San Donato Hospital
Diabetes mellitus treatment with stem cells in Italy usually costs from $15,000 to $30,000. Final prices depend on treatment complexity, the specific protocol used, and clinic accreditation level. Patients save around 44% compared to the US, where similar procedures average $40,000. Treatment typically includes initial diagnostics, cell therapy sessions, and specialist consultations.
Bookimed Expert Insight: Choosing an IRCCS-accredited facility like San Raffaele or San Donato Hospital ensures top-tier safety. These centers are recognized by the Italian Ministry of Health for research excellence. San Raffaele is particularly notable for pioneering the world's first stem cell therapy for rare diseases. While base consultations start around $400, the value lies in accessing 350+ specialized doctors. These institutions perform over 8,000 operations annually, providing high-volume clinical expertise for complex metabolic cases.
Why choose Italy for diabetes mellitus treatment with stem cells?
Access advanced Diabetes mellitus treatment with stem cells solutions in trusted clinics .
| Italy | Turkey | Austria | |
| Diabetes mellitus treatment with stem cells | from $15,000 | from $12,000 | from $25,000 |
No hidden fees – just official clinic prices. Pay at the clinic for Diabetes mellitus treatment with stem cells upon arrival and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Diabetes mellitus treatment with stem cells and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Diabetes mellitus treatment with stem cells journey.
Day 1
Day 2
Day 3
Day 4
Day 5
Day 6
Day 7
Week 1-3 post-operation
Week 4-6 post-operation
Please note that the recovery timeline may vary as each case is individual.
Written by Mariia Mytrofankina
Stem cell treatment for diabetes mellitus involves using regenerative therapy to repair or replace damaged pancreatic cells, aiming to improve insulin production and glucose control.
Stem cell therapies for diabetes are not yet approved for routine clinical use in Italy. These treatments remain strictly limited to clinical trials and experimental protocols under the Italian Medicines Agency (AIFA). Standard practice still relies on whole pancreas or donor islet transplants rather than stem cells.
Bookimed Expert Insight: San Raffaele Research Hospital holds a unique advantage as the world's first center to achieve approved stem cell therapy for other conditions. While diabetes treatments are experimental, this institutional experience ensures trials follow the highest safety protocols. Patients should prioritize these accredited research centers over private clinics to ensure clinical oversight.
Patient Consensus: Many patients emphasize that stem cell therapy is not a permanent cure. Most report insulin independence lasts about 1.5 years before needing standard backup medical technology again.
Main safety risks include tumor formation from undifferentiated cells and immune system rejection of transplanted material. Patients may also face inappropriate cell differentiation or vascular blockages from intravenous infusions. Medical facilities in Italy, like San Raffaele, prioritize IRCCS-accredited research standards to mitigate these serious clinical complications.
Bookimed Expert Insight: Safety significantly increases at Italian IRCCS research hospitals like San Raffaele in Milan. These centers hold Ministry of Health accreditation for genetic research. Choosing an academic facility over a private boutique clinic ensures adherence to rigorous EU clinical trial protocols. This oversight is vital as most diabetes stem cell treatments remain experimental worldwide.
Patient Consensus: Many patients emphasize the need to verify trial registration on the EU Clinical Trials Register. Others report severe fatigue or allergic responses and suggest keeping an endocrinologist involved throughout.
Italian and international clinical trials demonstrate improved diabetes control through automated technology, advanced drug therapies, and intensive metabolic interventions. Studies highlight Automated Insulin Delivery (AID) and weekly basal insulin as primary drivers in stabilizing HbA1c levels and increasing time in target glucose ranges.
Bookimed Expert Insight: Italy’s leadership in diabetes research is anchored by IRCCS-accredited centers like San Raffaele in Milan. These institutions operate as research hospitals, bridging the gap between clinical trials and bedside care. While stem cell protocols are emerging, the immediate benefit for patients lies in the integration of specialized technology within these research-heavy environments.
Ospedale San Raffaele in Milan leads Italian stem cell trials for diabetes through its Diabetes Research Institute. This IRCCS-accredited center conducts high-priority Phase 1/2 studies on allogeneic islet infusions and CRISPR-engineered immune-evasive cells. Other key sites include Galeazzi-Sant'Ambrogio and research hubs in Turin.
Bookimed Expert Insight: While San Raffaele handles over 300,000 patients yearly, their IRCCS status is the critical differentiator. This Italian Ministry of Health accreditation confirms they legally combine clinical assistance with active research. For patients, this means direct access to trials that private clinics cannot legally provide.
Patient Consensus: Patients emphasize verifying any Italian stem cell trial through official clinical registries before booking. Local communities warn about high costs and advise consulting endocrinologists to manage expectations regarding long-term results.
The Italian National Health Service (SSN) does not currently reimburse stem cell therapy for diabetes. While Italy covers stem cell treatments for specific hematological and genetic conditions, diabetes therapy remains experimental. The Italian Medicines Agency (AIFA) has not approved it for national reimbursement coverage.
Bookimed Expert Insight: While national reimbursement is unavailable, San Raffaele Hospital holds IRCCS accreditation from the Italian Ministry of Health. This status confirms their dual role in clinical care and pioneering research. Patients seeking cell-based interventions often find authorized research protocols at such institutions rather than through standard regional scripts. Experience at these centers is high, with San Raffaele performing over 52,000 operations annually across various specialties.
Patient Consensus: Current sentiment reflects the experimental nature of the treatment, with very limited public health coverage available. Patients suggest consulting an endocrinologist directly regarding specific regional policies or eligibility for active research protocols.
Patients enroll in Italian diabetes stem-cell trials by registering through the AIFA National Observatory or the EU Clinical Trials Register. Screening requires a referral from an endocrinologist. Leading centers like San Raffaele Hospital evaluate candidates based on HbA1c levels and pancreatic function.
Bookimed Expert Insight: Italian research centers often prioritize patients for gene therapy and stem-cell trials through specialized online second-opinion services. Institutions like San Raffaele use these digital consultations to filter international candidates before physical travel. This saves patients significant costs on preliminary diagnostic travel to Milan or Rome.
Patient Consensus: Patients emphasize that managing expectations regarding trial phases is vital for emotional stability. Most appreciate the thoroughness of Italian screening protocols as a sign of high safety standards.